Infection

, Volume 43, Issue 5, pp 545–550 | Cite as

Ertapenem usage in cancer patients with and without neutropenia: a report on 97 cases from a comprehensive cancer center

  • L. Nesher
  • F. P. Tverdek
  • S. N. Mahajan
  • R. F. Chemaly
  • Kenneth V. I. Rolston
Original Paper
First Online:
Received:
Accepted:

Abstract

Purpose

Ertapenem is being increasingly utilized in cancer patients, but published data regarding its usage are limited. Our objective was to describe the various indications for ertapenem therapy and its safety and efficacy in cancer patients.

Methods

We conducted a retrospective cohort study of cancer patients who received monotherapy with ertapenem for at least 72 h, between January 2007 and February 2013.

Results

Among 97 unique patients who received ertapenem monotherapy, the most common indications were: (1) To facilitate discharge from the hospital of stable patients still requiring antimicrobial therapy (46 %). (2) Primary therapy of various documented infections (bacteremia, pneumonia, urinary tract infection, skin and skin structure infection) with ertapenem (28 %). (3) De-escalation from a different broad-spectrum agent or regimen to ertapenem within the hospital setting in patients not ready for discharge (25 %). The median age of the 97 patients studied was 59 years (range 9–87 years) with 52 % being men. Most patients had underlying hematologic malignancies (54 %), and 7 % were recipients of hematopoietic stem cell transplantation. Twenty-nine patients (30 %) were neutropenic, 26 % were diabetic, and 6 % had chronic lung disease. Primary ertapenem monotherapy was successful in all patients, de-escalation in 95.8 % of patients, and the strategy of discharge on outpatient therapy with ertapenem in 95.6 % of patients. Patients failing de-escalation or early discharge responded to alternative regimens. We documented no significant ertapenem associated toxicity or adverse events.

Conclusions

Ertapenem appears to be safe and effective for several indications in cancer patients.

Keywords

Ertapenem  De-escalation Neutropenia Cancer patients 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This study was presented in part at The 49th Annual Meeting of Infectious Diseases Society of America (IDSA), Boston, MA, October 20–23, 2011. This work was supported in part by a research grant from Merck Inc., which did not have any role in the study design, collection, analysis or interpretation of data; nor did they have any influence on the writing of the report, or the decision to submit the article for publication.

Conflict of interest

All authors wish to declare that they have no conflicts of interest.

References

  1. 1.
    Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798–806.CrossRefPubMedGoogle Scholar
  2. 2.
    Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection. 2014;42:5–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. 2003.Google Scholar
  4. 4.
    Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003;37:1144–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefPubMedGoogle Scholar
  8. 8.
    Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw. 2012;10:1412–45.Google Scholar
  9. 9.
    Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995;20:1126–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005;104:205–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Talbot GH, Bradley J, Edwards JE, et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–68.CrossRefPubMedGoogle Scholar
  12. 12.
    Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.CrossRefPubMedGoogle Scholar
  13. 13.
    Infectious Diseases Society of A. The 10 × ‘20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50:1081–3.CrossRefGoogle Scholar
  14. 14.
    Boucher HW, Talbot GH, Benjamin DK, et al. 10 × ‘20 Progress–development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685–94.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.CrossRefPubMedGoogle Scholar
  16. 16.
    Goff DA, Mangino JE. Ertapenem: no effect on aerobic Gram-negative susceptibilities to imipenem. J Infect. 2008;57:123–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Rolston KV, LeBlanc BM, Streeter H, Ho DH. In vitro activity of ertapenem against bacterial isolates from cancer patients. Diagn Microbiol Infect Dis. 2002;43:219–23.CrossRefPubMedGoogle Scholar
  18. 18.
    Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis. 2010;67:266–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy. 2011;57:335–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Mahajan SN, Ariza-Heredia EJ, Rolston KV, et al. Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics. Ann Surg Oncol. 2014;21:513–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother. 2004;53(Suppl 2:ii):75–81.Google Scholar
  22. 22.
    Losco G, Studd R, Blackmore T. Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. BJU Int. 2014;113(Suppl 2):69–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis. 2011;70:367–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Nicolau DP, Carmeli Y, Crank CW, et al. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012;39:11–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Ahmad F, Pogue JM, Marchaim D, et al. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. J inf and pub hlth. 2014;7:50–3.Google Scholar
  27. 27.
    Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008;26:606–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol. 2011;29:3984–9.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993;71:36406.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • L. Nesher
    • 1
  • F. P. Tverdek
    • 1
  • S. N. Mahajan
    • 1
  • R. F. Chemaly
    • 1
  • Kenneth V. I. Rolston
    • 1
  1. 1.Department of Infectious Diseases, Infection Control and Employee HealthThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations